Translation Inhibition by Rocaglamide A Enhances Susceptibility of Yeasts to Caspofungin

Fks1 catalyzes the synthesis of {beta}-1,3-glucans, a major structural component of the fungal cell wall, and is the primary target of the antifungal drug caspofungin. Mutations in Fks1 confer caspofungin resistance by disrupting its interaction with the drug, thereby reducing inhibition of Fks1 enzymatic activity. Previous studies demonstrated that translation of the FKS1 mRNA was highly dependent on the translation initiation helicases eIF4A and Ded1 (1). Therefore, we investigated whether treatment of Saccharomyces cerevisiae cells with the eIF4A inhibitor Rocaglamide A (RocA) or mutation of Ded1 affects translation of FKS1 and susceptibility to caspofungin. Using WT and temperature-sensitive ded1-ts strains, we demonstrated that RocA enhanced caspofungin-mediated growth inhibition and translation repression. Sensitivity to both drugs was further enhanced in ded1-ts strains, suggesting specifically targeting Ded1 in fungi could be an effective mechanism to prevent caspofungin resistance. We extended the analysis to Candida glabrata, a related fungal pathogen, and found similar results. Importantly, combining RocA with caspofungin was fungicidal in both species, suggesting the combination could decrease development of caspofungin resistance in pathogenic yeasts. Together these findings highlight the potential of targeting translation initiation helicases for effective combination antifungal treatments.